Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:A Randomized Controlled Trial
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00196703|
Recruitment Status : Unknown
Verified March 2005 by Gabinete Berthier y Martínez.
Recruitment status was: Recruiting
First Posted : September 20, 2005
Last Update Posted : September 20, 2005
- Aphasia, the loss or impairment of language caused by brain damage, is one of the most devastating cognitive impairments of stroke. Aphasia can be treated with combination of speech-language therapy and drugs. Conventional speech-language therapy in chronic aphasic subjects is of little help and several drugs have been studied with limited success. Therefore other therapeutic strategies are warranted.
- Recent data suggest that drugs (memantine) acting on the brain chemical glutamate may help the recovery of cognitive deficits, included language, in subjects with vascular dementia. The present study examines the safety profile and efficacy of memantine paired with intensive language therapy in subjects with stroke-related chronic aphasia (more than 1 yr. of evolution).
|Condition or disease||Intervention/treatment||Phase|
|Aphasia Stroke||Drug: memantine Procedure: constraint-induced language therapy||Phase 4|
- The efficacy of drugs that act on glutamate such as the N-methyl-D-aspartic acid (NMDA) receptor antagonist memantine requires to be explored in this population. The rationale for using memantine in post-stroke aphasia comes from recent studies on vascular dementia. Data extracted from a recent Cochrane review of randomized controlled trials of memantine in different types of dementia (vascular dementia, Alzheimer's disease, mixed dementia) reveal, after 6 weeks of treatment, beneficial effects on cognition (including language), activities of daily living, behavior and global scales as well as in the global impression of change.
- Recovery from aphasia is possible even in severe cases. While speech-language therapy remains as the mainstay treatment of aphasia, its effectiveness has not been conclusively proved. This has motivated the planning of more rational therapies (e.g., constraint-induced language therapy [Pulvermüller et al., 2001; 32: 1621-1626]).
- In addition, the neural correlates of improvement of language function can now be readily detectable with event-related potentials. This is a noninvasive technique that can detect in real time functional brain changes during recovery promoted by the combined action of memantine and constraint-induced language therapy.
- The aim of the present study is to assess the efficacy, safety profile, and functional correlates of memantine paired with massed language therapy in a sample of patients with chronic poststroke aphasia.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A 24-Week Pilot, Double-Blind, Randomized, Parallel, Placebo-Controlled Study of Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:Correlation With Cognitive Evoked Potentials During Recovery.|
|Study Start Date :||March 2005|
|Estimated Study Completion Date :||September 2005|
- Language function (overall aphasia severity).
- Cognitive evaluation of language function
- Changes in event-related potential
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00196703
|Contact: Marcelo L. Berthier, M.D., Ph.D.||(34) 952 22 45 firstname.lastname@example.org|
|Gabinete Berthier y Martínez and Centro de Investigaciones Médico-Sanitarias (CIMES) University of Malaga||Recruiting|
|Malaga, Spain, 29001|
|Contact: Marcelo L. Berthier, M.D., Ph.D (34) 952 22 45 90 email@example.com|
|Sub-Investigator: Cristina Green, Ph.D.|
|Sub-Investigator: Carolina Higueras, Ph.D.|
|Sub-Investigator: Pablo Lara, M.D., Ph.D.|
|Sub-Investigator: Carmen Montes, M.D., Ph.D|
|Principal Investigator: Marcelo L. Berthier, M.D., Ph.D|
|Principal Investigator:||Marcelo L. Berthier, M.D., Ph.D||Gabinete Berthier y Martínez and Centro de Investigaciones Médico-Sanitarias (CIMES), University of Malaga|